Your session is about to expire
← Back to Search
Atezolizumab for Breast Cancer (IMpassion050 Trial)
IMpassion050 Trial Summary
This trial will compare atezolizumab to placebo in neoadjuvant treatment for early HER2-positive breast cancer.
- Breast Cancer
IMpassion050 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227IMpassion050 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the Atezolizumab FDA approval status?
"Power's team has given Atezolizumab a safety rating of 3. This is due to the fact that this drug has completed Phase 3 clinical trials, meaning that there is both efficacy and safety data available."
Could you please share if there is any existing research on Atezolizumab?
"Atezolizumab was first studied in 1997 at Spectrum Health Hospital. As of now, there have been 20886 completed trials and 2228 live trials. The majority of these ongoing studies are based in New york City."
How many subjects are trialing this medication?
"This clinical trial is not currently looking for new patients, as it has already reached its recruitment goals. The study was originally posted on 1/11/2019 and was last updated on 8/29/2022. However, there are 2677 other trials actively recruiting participants with breast cancer and 2228 trials for Atezolizumab actively admitting patients."
Share this study with friends
Copy Link
Messenger